The treatment of glioblastoma with nimustine and teniposide appeared to be as effective as temozolomide (TMZ) but was much less costly. The author of this report suggests initiating a new phase 3 trial comparing the 2 regimens to determine whether, despite its disproportionately higher cost, TMZ is justified further as standard for the treatment of this tumor entity.
No takes yet. Share an insight, caveat, or question.
Ute Linz (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: